Mittwoch, 25. Dezember 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Rekrutierend

NCT-Nummer:
NCT05566795

Studienbeginn:
Februar 2023

Letztes Update:
06.08.2024

Wirkstoff:
Chemotherapeutic Agent, Tovorafenib

Indikation (Clinical Trials):
Glioma

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
Phase 3

Sponsor:
Day One Biopharmaceuticals, Inc.

Collaborator:
SIOPe Brain Tumor Group LOGGIC Consortium

Kontakt

Day One Clinical Trials Information
Kontakt:
Phone: 650-484-0899
E-Mail: clinicaltrials@dayonebio.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 102)

Universitätsklinikum Freiburg
79106 Freiburg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Universitätsklinikum Augsburg
86156 Augsburg
(Bayern)
GermanyRekrutierend» Google-Maps
Onkologisches Zentrum Universitätsklinikum Würzburg
Josef-Schneider-Straße 6
97080 Würzburg
DeutschlandRekrutierend» Google-Maps
Universitätsklinikum Frankfurt
60590 Frankfurt
(Hessen)
GermanyRekrutierend» Google-Maps
Gynäkologisches Tumorzentrum am Universitätsklinikum Leipzig
4103 Leipzig
DeutschlandRekrutierend» Google-Maps
Charité Universitätsmedizin Berlin
13353 Berlin
(Berlin)
GermanyRekrutierend» Google-Maps
Evangelische Klinikum Bethel (EvKB)
33617 Bielefeld
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Brustzentrum am Universitätsklinikum Hamburg-Eppendorf
Martinistraße 52
20251 Hamburg
DeutschlandRekrutierend» Google-Maps
Universitätsklinikum Heidelberg
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Viszeralonkologisches Zentrum Universitätsklinikum Tübingen
Hoppe-Seyler-Straße 3
72076 Tübingen
DeutschlandRekrutierend» Google-Maps
Hautkrebszentrum Universitätsklinikum Erlangen
Ulmenweg 18
91054 Erlangen
(Bayern)
DeutschlandRekrutierend» Google-Maps
Children's of Alabama
35233 Birmingham
United StatesRekrutierend» Google-Maps
Phoenix Children's Hospital
85016 Phoenix
United StatesRekrutierend» Google-Maps
Children's Hospital Los Angeles
90027 Los Angeles
United StatesRekrutierend» Google-Maps
UCSF Benioff Children's Hospital
94158 San Francisco
United StatesRekrutierend» Google-Maps
Children's Hospital Colorado
80045 Aurora
United StatesRekrutierend» Google-Maps
Children's National Medical Center
20010 Washington
United StatesRekrutierend» Google-Maps
Arnold Palmer Hospital for Children
32806 Orlando
United StatesRekrutierend» Google-Maps
Children's Healthcare of Atlanta
30322 Atlanta
United StatesRekrutierend» Google-Maps
Ann & Robert H. Lurie Children's Hospital of Chicago
60611 Chicago
United StatesRekrutierend» Google-Maps
Riley Hospital for Children at Indiana University Health
46202 Indianapolis
United StatesRekrutierend» Google-Maps
Dana-Farber Cancer Institute
02215 Boston
United StatesRekrutierend» Google-Maps
University of Michigan - - C.S. Mott Children's Hospital
48109 Ann Arbor
United StatesRekrutierend» Google-Maps
St. Louis Children's Hospital
63110 Saint Louis
United StatesRekrutierend» Google-Maps
New York University Langone Health
10016 New York
United StatesRekrutierend» Google-Maps
University of Rochester
14642 Rochester
United StatesRekrutierend» Google-Maps
Cleveland Clinic Main Campus
44195 Cleveland
United StatesRekrutierend» Google-Maps
University of Texas Southwestern Medical Center
75390 Dallas
United StatesRekrutierend» Google-Maps
Texas Children's Hospital
77030 Houston
United StatesRekrutierend» Google-Maps
Seattle Children's Hospital
98105 Seattle
United StatesRekrutierend» Google-Maps
Children's Health Queensland Hospital and Health Service
4101 South Brisbane
AustraliaRekrutierend» Google-Maps
Women's and Children's Health Network
5006 North Adelaide
AustraliaRekrutierend» Google-Maps
The Royal Children's Hospital - Children's Cancer Centre
3052 Parkville
AustraliaRekrutierend» Google-Maps
Sydney Children's Hospital - Randwick
2031 Randwick
AustraliaRekrutierend» Google-Maps
Children's Hospital at Westmead
2145 Westmead
AustraliaRekrutierend» Google-Maps
Medizinische Universität Innsbruck
6020 Innsbruck
AustriaRekrutierend» Google-Maps
Cliniques Universitaires Saint-Luc
1200 Brussel
BelgiumRekrutierend» Google-Maps
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
3000 Leuven
BelgiumRekrutierend» Google-Maps
Alberta Children's Hospital
T3B 6A8 Calgary
CanadaRekrutierend» Google-Maps
British Columbia Children's Hospital
V6H 3N1 Vancouver
CanadaRekrutierend» Google-Maps
The Montreal Children's Hospital
H4A 3J1 Montréal
CanadaRekrutierend» Google-Maps
Centre Hospitalier de l'Université Laval et Centre Mère-Enfant Soleil
G1V 4G2 Québec
CanadaRekrutierend» Google-Maps
SickKids - The Hospital for Sick Children
M5G 1X8 Toronto
CanadaRekrutierend» Google-Maps
Fakultní Nemocnice Brno - D?tská Nemocnice
625 00 Brno
CzechiaRekrutierend» Google-Maps
Helsingin yliopistollinen sairaala (HUS)
FI-00290 Helsinki
FinlandRekrutierend» Google-Maps
Tampereen Yliopistollinen Sairaala
33520 Tampere
FinlandRekrutierend» Google-Maps
Centre de Lutte contre le Cancer - Centre Oscar Lambret
59020 Lille
FranceRekrutierend» Google-Maps
Aghia Sofia General Children's Hospital
11527 Athens
GreeceRekrutierend» Google-Maps
Athens General Children's Hospital
11527 Athens
GreeceRekrutierend» Google-Maps
Semmelweis Egyetem Tűzoltó utcai II. Sz. Gyermekgyógyászati Kliniká
1094 Budapest
HungaryRekrutierend» Google-Maps
Children's Health Ireland at Crumlin
D12 N512 Crumlin
IrelandRekrutierend» Google-Maps
Schneider Children's Medical Center of Israel
49202 Petah tikva
IsraelRekrutierend» Google-Maps
The Edmond and Lily Safra Children's Hospital
5265601 Ramat Gan
IsraelRekrutierend» Google-Maps
Fondazione IRCCS - Istituto Nazionale dei Tumori
20133 Milano
ItalyRekrutierend» Google-Maps
Ospedale Pediatrico Bambino Gesù
00165 Roma
ItalyRekrutierend» Google-Maps
Ospedale Infantile Regina Margherita
10126 Torino
ItalyRekrutierend» Google-Maps
Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari
70124 Bari
ItalyRekrutierend» Google-Maps
Azienda Ospedaliera di Rilievo Nazional Santobono Pausilipon
80131 Napoli
ItalyRekrutierend» Google-Maps
Azienda Ospedale Università di Padova
35128 Padova
ItalyRekrutierend» Google-Maps
Azienda Sanitaria Universitaria Friuli Centrale - P.O. Santa Maria della Misericordia
33100 Udine
ItalyRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Prinses Maxima Centrum Kinderoncologie
3584 CS Utrecht
NetherlandsRekrutierend» Google-Maps
Starship Paediatric Blood & Cancer Center
1023 Grafton
New ZealandRekrutierend» Google-Maps
Universitetssykehuset Nord-Norge - Tromsø
9038 Tromsø
NorwayRekrutierend» Google-Maps
SingHealth Group - KK Women's and Children's Hospital
229899 Singapore
SingaporeRekrutierend» Google-Maps
Univerzitetni Klinini Center Ljubljana
1000 Ljubljana
SloveniaRekrutierend» Google-Maps
Hospital Universitario Cruces
48903 Barakaldo
SpainRekrutierend» Google-Maps
Hospital Universitari Vall d'Hebrón
08035 Barcelona
SpainRekrutierend» Google-Maps
Hospital Sant Joan de Déu Barcelona
08950 Barcelona
SpainRekrutierend» Google-Maps
Hospital Infantil Universitario Niño Jesús
28009 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen del Rocío
41013 Sevilla
SpainRekrutierend» Google-Maps
Hospital Universitari i Politècnic La Fe
46026 Valencia
SpainRekrutierend» Google-Maps
Drottning Silvias barn- och ungdomssjukhus
416 85 Göteborg
SwedenRekrutierend» Google-Maps
Skånes Universitetssjukhus - Lund
221 85 Lund
SwedenRekrutierend» Google-Maps
Astrid Lindgrens Barnsjukhus Solna
171 77 Stockholm
SwedenRekrutierend» Google-Maps
Centre Hospitalier Universitaire Vaudois Lausanne
1011 Lausanne
SwitzerlandRekrutierend» Google-Maps
Universitaets - Kinderspital Zürich
8032 Zurich
SwitzerlandRekrutierend» Google-Maps
Birmingham Women's and Children's NHS Foundation Trust
B4 6NH Birmingham
United KingdomRekrutierend» Google-Maps
Leeds Teaching Hospital NHS Trust
LS1 3EX Leeds
United KingdomRekrutierend» Google-Maps
Manchester University NHS Foundation Trust
M13 PWL Manchester
United KingdomRekrutierend» Google-Maps
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
NE1 4LP Newcastle Upon Tyne
United KingdomRekrutierend» Google-Maps
Great Ormond Street Hospital for Children
WC1N 3JH Oxford
United KingdomRekrutierend» Google-Maps
NHS Greater Glasgow and Clyde
G51 4TF Glasgow
United KingdomRekrutierend» Google-Maps
The Royal Marsden NHS Foundation Trust
SM2 5PT Sutton
United KingdomRekrutierend» Google-Maps
University Hospitals Bristol and Weston NHS Foundation Trust
BS2 8HW Bristol
United KingdomRekrutierend» Google-Maps
Cambridge University Hospitals NHS Foundation Trust
CB2 0QQ Cambridge
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

Approximately 400 treatment-naïve low-grade glioma patients will be randomized 1:1 to

either tovorafenib (Arm 1) or an Investigator's choice of SoC chemotherapy (Arm 2).

Arm 1 (tovorafenib): treatment cycles will repeat every 28 days in the absence of disease

progression. Patients will continue tovorafenib until any of the following occurs:

disease progression based on Response Assessment in Neuro-Oncology (RANO-LGG) criteria,

unacceptable toxicity, withdrawal of consent to treatment, or end of study.

Arm 2 (Investigator's Choice of SoC Chemotherapy): patients will receive one of 3 SoC

chemotherapy options selected by the treating Investigator: Children's Oncology Group -

Vincristine/Carboplatin (COG-V/C) regimen, International Society for Paediatric Oncology

- Low-Grade Glioma Vincristine/Carboplatin (SIOPe-LGG-V/C) regimen, or vinblastine (VBL)

regimen. The choice of SoC chemotherapy regimen will be selected prior to patient

randomization. Treatment will continue until completion of therapy or until any of the

following occurs: disease progression based on RANO-LGG criteria, unacceptable toxicity,

withdrawal of consent to treatment, or end of study.

Patients who discontinue treatment due to disease progression will have (1) radiographic

evidence of progressive disease based on RANO-LGG, as determined by the Investigator and

confirmed by the IRC, or (2) clinical progression based on RANO-LGG criteria determined

by the Investigator. Investigators are encouraged to discuss cases of clinical

progression and early radiographic progression without clinical symptom with the Sponsor

Medical Monitor prior to treatment discontinuation or initiation of a different form of

treatment for the malignancy. Patients may continue therapy beyond progressive disease

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Less than 25 years of age with LGG with known activating RAF alteration

- Histopathologic diagnosis of glioma or glioneuronal tumor

- At least one measurable lesion as defined by RANO criteria

- Meet indication for first-line systemic therapy

Exclusion Criteria:

- Patient has any of the following tumor-histological findings:

1. Schwannoma

2. Subependymal giant cell astrocytoma (Tuberous Sclerosis)

3. Diffuse intrinsic pontine glioma, even if histologically diagnosed as World

Health Organization (WHO) Grade I-II

- Patient's tumor has additional pathogenic molecular alterations, including but not

limited to a) IDH 1/2 mutation, b) Histone H3 mutation, and c) NF-1 loss of function

alteration.

- Known or suspected diagnosis of neurofibromatosis Type 1 or 2 (NF-1/NF-2)

- Prior or ongoing nonsurgical anticancer therapy for this indication (eg,

chemotherapy, oral/intravenous targeted therapy) including radiation

Studien-Rationale

Primary outcome:

1. Compare the objective response rate (ORR) assessed per RANO-LGG criteria by Independent Review Committee (IRC) of tovorafenib monotherapy versus standard of care (SoC) chemotherapy (Time Frame - Up to 60 months):
ORR, per RANO-LGG criteria, defined as the proportion of patients with overall confirmed response of complete response (CR) or partial response (PR)



Secondary outcome:

1. Compare the progression-free survival (PFS) assessed by IRC of tovorafenib monotherapy versus SoC chemotherapy per RANO-LGG criteria (Time Frame - Up to 60 months):
PFS per RANO-LGG criteria, defined as time from randomization to PD or death from any cause

2. Compare the duration of response (DOR) assessed by IRC of tovorafenib monotherapy versus SoC chemotherapy per RANO-LGG criteria (Time Frame - Up to 60 months):
DOR per RANO-LGG criteria, defined as time from confirmed response to PD or death from any cause for patients with confirmed response

3. Compare the overall survival (OS) of tovorafenib monotherapy versus SoC chemotherapy (Time Frame - Up to 60 months):
OS, defined as time from randomization up to death from any cause

4. Compare the safety and tolerability of tovorafenib monotherapy versus SoC chemotherapy (Time Frame - Up to 60 months):
Type, frequency, and severity of treatment-emergent adverse events

5. Compare the safety and tolerability of tovorafenib monotherapy versus SoC chemotherapy (Time Frame - Up to 60 months):
Measured by incidence of clinically significant laboratory abnormalities

6. Evaluate changes in neurological function and adaptive behavior between tovorafenib versus SoC (Time Frame - Up to 60 months):
Change from baseline in the Vineland Adaptive Behavior Composite Scales [age-adjusted standard scores range between 20 to 140, with a mean of 100 and standard deviation of 15, and lower scores indicate worse functional outcomes]

7. Compare changes in visual function outcomes of tovorafenib monotherapy versus SoC chemotherapy in patients with optic pathway glioma (OPG) (Time Frame - Up to 60 months):
Measured by Teller Acuity Cards® or alternative

8. Compare the ORR of tovorafenib monotherapy versus SoC chemotherapy as assessed by IRC per RANO-HGG and Response Assessment in Pediatric Neuro-Oncology (RAPNO-LGG) criteria (Time Frame - Up to 60 months):
ORR, defined as the proportion of patients with overall confirmed response per RANO-HGG, RANO-LGG, or RAPNO-LGG criteria.

9. Compare the clinical benefit rate (CBR) of tovorafenib monotherapy versus SoC chemotherapy as assessed by IRC per RANO-LGG, RANO-HGG and RAPNO-LGG criteria (Time Frame - Up to 60 months):
CBR, defined as the proportion of patients with radiological tumor stabilization or regression per RANO-LGG, RANO-HGG or RAPNO-LGG criteria, as applicable

10. Compare time to response (TTR) of tovorafenib monotherapy versus SoC chemotherapy as assessed by IRC per RANO-LGG, RANO-HGG and RAPNO-LGG criteria (Time Frame - Up to 60 months):
Measured by the time to first response following initiation of therapy in patients with best overall confirmed response per RANO-LGG, RANO-HGG or RAPNO-LGG criteria, as applicable

11. Compare the PFS of tovorafenib monotherapy versus SoC chemotherapy as assessed by IRC per RAPNO-LGG and RANO-HGG criteria (Time Frame - Up to 60 months):
PFS per RANO-HGG or RAPNO-LGG (as applicable), defined as time from randomization to progressive disease (PD) or death from any cause

12. Compare the DOR of tovorafenib monotherapy versus SoC chemotherapy as assessed by IRC per RAPNO-LGG and RANO-HGG criteria (Time Frame - Up to 60 months):
DOR, defined as time from confirmed response to PD or death from any cause for patients with confirmed response per RANO or RAPNO criteria, as applicable

13. Evaluate the health-related quality of life (HRQoL) in tovorafenib versus SoC chemotherapy using Patient-Reported Outcomes Measurement Information System (PROMIS) test battery (Time Frame - Up to 60 months):
Measured by change from baseline in Total Score at 1, 2, 5 years

Studien-Arme

  • Experimental: Arm #1
    Tovorafenib
  • Active Comparator: Arm #2
    Investigator's choice of one of the following current standard of care for pediatric patients with low-grade gliomas: 1. Children's Oncology Group - Vincristine/Carboplatin (COG-V/C) 2. International Society for Paediatric Oncology - Low-Grade Glioma Vincristine/Carboplatin (SIOPe-LGG-V/C) 3. Vinblastine (VBL)

Geprüfte Regime

  • Tovorafenib (DAY101, Ojemda):
    Oral type II RAF kinase inhibitor
  • Chemotherapeutic Agent (COG-V/C / SIOPe-LGG-V/C / VBL / ):
    Intravenous solution for injection

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.